FDA Warns of Risk for Delayed-onset Inflammation Near Dermal Filler Sites

July 13, 2023
Injection of facial filler

The US Food and Drug Administration updated its informational webpage on dermal fillers to reflect the risk of delayed-onset inflammation near dermal filler treatment sites.

The webpage now includes mention of delayed-onset inflammation near the dermal filler treatment site following viral or bacterial illnesses or infections, vaccinations, or dental procedures along with risk of bruising, redness, swelling, and pain.

Typically, the reported inflammation is responsive to treatment or resolves on its own. The FDA encourages consumers and patients to discuss all treatment options, including dermal filler procedures, with their health care provider to understand the benefits and risks associated with the use of these medical devices, the FDA notes.

Read more at Modern Aesthetics >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Candela Becomes Platinum Vendor Affiliate with the American Med Spa Association
    • FDA Approves Additional Warning for Kybella Labeling
    • Federal Bill Would Establish New Ownership and Management Requirements for Medical Practices
    • CBS News Investigation Raises Concerns About Unapproved Retatrutide Sales
    • Beyond Either/Or: Building Integrated Treatment Plans with Energy-Based Devices and Injectables